Annual report pursuant to Section 13 and 15(d)

Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)

v3.22.1
Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)
 12 Months Ended
May 24, 2021
USD ($)
Jun. 11, 2020
USD ($)
$ / shares
shares
Dec. 04, 2019
USD ($)
Jul. 26, 2016
shares
Jul. 22, 2016
Dec. 31, 2021
USD ($)
item
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
shares
Dec. 04, 2020
shares
Nov. 11, 2020
$ / shares
shares
Nov. 10, 2020
shares
Jul. 13, 2018
shares
Dec. 31, 2016
USD ($)
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Common stock, shares authorized           150,000,000 125,000,000   125,000,000 125,000,000 85,000,000    
Common stock par value (in dollars per share) | $ / shares           $ 0.0001 $ 0.0001     $ 0.0001      
Preferred stock, shares authorized           2,000,000 2,000,000            
Preferred stock, shares issued           250,000 250,000            
Aggregate value of shares subscribed | $           $ 4,329,000 $ 7,939,000            
Common stock, shares issuable           2,536,607 2,103,122            
Proceeds from issuance of common shares | $           $ 0 $ 37,230,000            
Aggregate fees of stock issuance | $           $ 0 $ 2,388,000            
Shares available for future sale           744,823              
Fortress Biotech, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Percentage of fully diluted equity           2.50% 2.50%            
Expenses from related party transaction | $           $ 500,000 $ 500,000            
Aggregate value of shares subscribed | $                         $ 900
Stock dividend (as a percent)       2.50%                  
At the Market Offering [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Agent commission (as a percent)                       3.00%  
Issuance of common shares (in shares)           19,400,000 17,600,000            
Shares issued, price per share | $ / shares           $ 3.70 $ 3.40            
Proceeds from issuance of common shares | $           $ 71,900,000 $ 59,800,000            
Aggregate fees of stock issuance | $           1,300,000 1,100,000            
Proceeds from issuance of Common Stock, net of offering costs | $           $ 70,600,000 $ 58,700,000            
At the Market Offering [Member] | Maximum                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Common stock, shares authorized                       75,000,000.0  
At the Market Offering [Member] | Fortress Biotech, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Issuance of common shares - Founders Agreement (in shares)           576,157 342,773 286,390          
Sale of Stock aggregate offering price - Founders Agreement | $           $ 71,900,000 $ 59,800,000 $ 37,200,000          
Percentage of fully diluted equity           2.50% 2.50% 2.50%          
Common shares issuable recorded - Founders Agreement           51,295 101,632            
Issuance of common shares (in shares)           576,157              
Common stock, shares issuable           51,295 101,632            
Proceeds from issuance of common shares | $           $ 71,900,000 $ 59,800,000            
Public Offering [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Issuance of common shares (in shares)   10,769,231                      
Shares issued, price per share | $ / shares   $ 3.25                      
Proceeds from issuance of common shares | $   $ 37,200,000                      
Aggregate fees of stock issuance | $   2,400,000                      
Proceeds from issuance of Common Stock, net of offering costs | $   $ 34,800,000                      
Number of stock options exercised   686,373                      
Public Offering [Member] | Fortress Biotech, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Issuance of common shares - Founders Agreement (in shares)             286,390            
Percentage of fully diluted equity             2.50%            
Proceeds from issuance of common shares | $             $ 37,200,000            
Over-Allotment Option [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Issuance of common shares (in shares)   1,615,384                      
Registration Statements [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Shares available for future issuance - Founders Agreement | $           $ 14,600,000              
Registration Statements [Member] | Maximum                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Shelf Registration statement, value of securities authorized to be sold | $ $ 200,000,000.0   $ 100,000,000.0                    
Common Stock [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of votes per share | item           1              
Common Stock [Member] | Fortress Biotech, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Common stock, shares issuable                         2,000,000
Class A Common Shares [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Common stock, shares authorized             1,000,000            
Director appointment right, period           10 years              
Common stock, shares issued           845,385 845,385            
Class B Common Shares [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of votes per share | item           1.1              
Class B Common Shares [Member] | Fortress Biotech, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares converted       7,250,000                  
Common stock, shares issuable                         7,000,000
Preferred Class A [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Preferred stock, shares issued             250,000            
Preferred Class A [Member] | Fortress Biotech, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Percentage of fully diluted equity         2.50%                
Number of shares issued in conversion       250,000                  
General and administrative [Member] | At the Market Offering [Member] | Fortress Biotech, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Expenses from related party transaction | $           $ 1,900,000 $ 1,500,000            
General and administrative [Member] | Public Offering [Member] | Fortress Biotech, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Expenses from related party transaction | $             $ 900,000